Thomas Wubben
Ophthalmology · Ann Arbor, MINPI 1265872006
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,325 of the $5,572 with a category attached, or 95.6%. Insmed, Inc. accounts for 63.0% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $3,631, more than ten times the $92 reported in 2023.
Across 7 payments — averaging $795.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$4K
- Johnson & Johnson$2K
- Dompe US, Inc.$121
- Janssen Research & Development, LLC$92
- Agios Pharmaceuticals, Inc.$34
Across 39 payments — averaging $30,485 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.2M
What the payments were for
- Consulting fees$5,32596%
- Food & beverage$2474%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 3 | $3,510 |
| Johnson & Johnson | 1 | $1,815 |
| Dompe US, Inc. | 1 | $121 |
| Janssen Research & Development, LLC | 1 | $92 |
| Agios Pharmaceuticals, Inc. | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oxervate$121
How this compares
$5,572 in reported general payments places this provider in the 85th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 56 | $2,479 |
| Ketorolac Tromethamine | 59 | $937 |
| Brimonidine Tartrate | 14 | $208 |
| Latanoprost | 12 | $174 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 11 | $134 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Ann Arbor
- Manjool ShahAnn Arbor$609K
- David ZacksAnn Arbor$177K
- Jason MillerAnn Arbor$104K
- Yannis PaulusAnn Arbor$85K
- Shilpa KodatiAnn Arbor$75K
- Amanda BicketAnn Arbor$34K
- Vinay AakaluAnn Arbor$16K
- Nita ValikodathAnn Arbor$16K
- Marguerite WeinertAnn Arbor$16K
- Abigail FahimAnn Arbor$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.